Presse medicale (Paris, France : 1983) · 1995
[Circulating antigliadin antibodies. Prevalence in a diabetic (type 1 or 2) and non diabetic adult population].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tourniaire J, Guichard-Rode S, Monier J C
Аннотация
OBJECTIVES: The level of circulating antigliadin antibodies is an essential element in diabetic patients with signs of coeliac disease. Intolerance to gluten can disrupt glucose regulation leading to greater risk of hypoglycaemia. Search for antigliadin antibodies could be a routine test in diabetics.
METHODS: Plasma gliadin antibodies were measured by immunoenzymatic assay in adult subjects: 80 type 1 diabetics, 80 type 2 diabetics, 80 non diabetics without auto-immune disease.
RESULTS: IgA antibodies were present in 6 type 1 diabetics (7.5%), 8 type 2 diabetics (10%) and 6 non-diabetics (7.5%). Anti-reticulin and anti-endomysium antibodies were measured in type 1 diabetics with antigliadine antibodies. They were present only in one patient (Tunisian) who suffered from a coeliac disease.
CONCLUSION: In France, the prevalence of coeliac disease is very low. Antigliadin antibodies measurement is justified only in patients with clinical and/or biological symptoms of coeliac disease.
METHODS: Plasma gliadin antibodies were measured by immunoenzymatic assay in adult subjects: 80 type 1 diabetics, 80 type 2 diabetics, 80 non diabetics without auto-immune disease.
RESULTS: IgA antibodies were present in 6 type 1 diabetics (7.5%), 8 type 2 diabetics (10%) and 6 non-diabetics (7.5%). Anti-reticulin and anti-endomysium antibodies were measured in type 1 diabetics with antigliadine antibodies. They were present only in one patient (Tunisian) who suffered from a coeliac disease.
CONCLUSION: In France, the prevalence of coeliac disease is very low. Antigliadin antibodies measurement is justified only in patients with clinical and/or biological symptoms of coeliac disease.